The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer (original) (raw)
Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis
Wenyi Gu
International journal of nanomedicine, 2016
View PDFchevron_right
The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer
Margaret Schwarz
Journal of Cellular Biochemistry, 2012
View PDFchevron_right
The Dual PI3K/mTOR Inhibitor BEZ235 Is Effective in Lung Cancer Cell Lines
Rudolf Huber
Anticancer Research, 2011
View PDFchevron_right
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
Wei Chen
PLoS ONE, 2011
View PDFchevron_right
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
Serena Di Cosimo
Cancer Research, 2008
View PDFchevron_right
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Vincent Duval
Cancer chemotherapy and pharmacology, 2018
View PDFchevron_right
A new paradigm of chemotherapy for gastric cancer: speeding up, and more clinical trials to catch up
Junichi Sakamoto
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2002
View PDFchevron_right
Superior Antitumor Activity of Nanoparticle Albumin-Bound Paclitaxel in Experimental Gastric Cancer
Margaret Schwarz
PLoS ONE, 2013
View PDFchevron_right
Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer
Bogdan-Ioan Coculescu
International journal of molecular sciences, 2024
View PDFchevron_right
The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines
Kurt Buchegger Mena, Ismael Riquelme, Pamela Leal, Carolina Bizama
Pathology oncology research : POR, 2016
View PDFchevron_right
MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of akt phosphorylation
Leimin Sun, Xingkang He
View PDFchevron_right
Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer
Margaret Schwarz
Molecular Cancer Therapeutics, 2014
View PDFchevron_right
The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance
Susana Aedo, Alejandra Sandoval, Ismael Riquelme
Virchows Archiv, 2014
View PDFchevron_right
Investigation of the effects of drugs effective on PI3K-AKT signaling pathway in colorectal cancer alone and in combination
Ahmet Altun
Cumhuriyet Medical Journal, 2014
View PDFchevron_right
NVP-BEZ235, a dual PI3K-mTOR inhibitor, suppresses the growth of FaDu hypopharyngeal squamous cell carcinoma and has a synergistic effect with Cisplatin
Sheng-fung Lin
Cell death discovery, 2018
View PDFchevron_right
Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer
Maliheh Moradzadeh
Middle East Journal of Digestive Diseases, 2018
View PDFchevron_right
Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells
Nafiseh Esmaeil
Biomedicine & Pharmacotherapy, 2017
View PDFchevron_right
Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
Chris Buhr, Artur Plonowski
Molecular Cancer Therapeutics, 2014
View PDFchevron_right
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas
Katsutoshi Oda
PloS one, 2012
View PDFchevron_right
PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced
Pascal Gauduchon
Cancer Letters, 2014
View PDFchevron_right
BET inhibition as a new strategy for the treatment of gastric cancer
Rommel Burbano
Oncotarget, 2016
View PDFchevron_right
PI3K/Akt/mTOR Pathway Dual Inhibitor BEZ235 Suppresses the Stemness of Colon Cancer Stem Cells
Wenyi Gu
Clinical and experimental pharmacology & physiology, 2015
View PDFchevron_right
VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer
kantharaj ethirajulu
View PDFchevron_right
Prognostic implications of phosphatidylinositol 3-kinase/AKT signaling pathway activation in gastric carcinomas
Luiz Lima
Archives of Medical Science, 2016
View PDFchevron_right
mTOR Inhibition Elicits a Dramatic Response in PI3K-Dependent Colon Cancers
Mohammed Farhoud, R. Halberg
PLoS ONE, 2013
View PDFchevron_right
RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth
Alexander Cao
PLoS ONE, 2012
View PDFchevron_right
First-In-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR In Patients With Advanced Cancer
Jorge Gallo, Lixin Han
View PDFchevron_right
Low-dose paclitaxel modulates tumour fibrosis in gastric cancer
Sachio Fushida
International journal of oncology, 2013
View PDFchevron_right
MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines
Saad kazim
Cancer Biology & Therapy, 2013
View PDFchevron_right
BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
jiryeon jang
Translational Oncology, 2016
View PDFchevron_right
The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
Ayman Alameen, Giorgio Zauli, Carolina Simioni
Oncotarget, 2015
View PDFchevron_right